Cogent Biosciences, Inc. Quarterly Operating Income (Loss) in USD from Q1 2017 to Q3 2024

Taxonomy & unit: us-gaap: USD
Description: The net result for the period of deducting operating expenses from operating revenues.
Summary: Cogent Biosciences, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2017 to Q3 2024.
Cogent Biosciences, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$75.4M, a 26.6% decline year-over-year.
Cogent Biosciences, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$260M, a 34.5% decline year-over-year.
Cogent Biosciences, Inc. annual Operating Income (Loss) for 2023 was -$208M, a 40.8% decline from 2022.
Cogent Biosciences, Inc. annual Operating Income (Loss) for 2022 was -$148M, a 95.7% decline from 2021.
Cogent Biosciences, Inc. annual Operating Income (Loss) for 2021 was -$75.6M, a 8.09% increase from 2020.

Operating Income (Loss), Trailing 12 Months (USD)

Operating Income (Loss), Quarterly (USD)

Operating Income (Loss), YoY Quarterly Growth (%)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed
Q3 2024	-$260M	-$75.4M	-$15.8M	-26.6%	Jul 1, 2024	Sep 30, 2024	10-Q	2024-11-12
Q2 2024	-$245M	-$64.4M	-$17.3M	-36.7%	Apr 1, 2024	Jun 30, 2024	10-Q	2024-08-06
Q1 2024	-$227M	-$62.4M	-$19.2M	-44.3%	Jan 1, 2024	Mar 31, 2024	10-Q	2024-05-07
Q4 2023	-$208M	-$58.2M	-$14.5M	-33.1%	Oct 1, 2023	Dec 31, 2023	10-K	2024-02-26
Q3 2023	-$194M	-$59.6M	-$22.8M	-61.8%	Jul 1, 2023	Sep 30, 2023	10-Q	2024-11-12
Q2 2023	-$171M	-$47.1M	-$11.2M	-31.3%	Apr 1, 2023	Jun 30, 2023	10-Q	2024-08-06
Q1 2023	-$160M	-$43.2M	-$11.8M	-37.6%	Jan 1, 2023	Mar 31, 2023	10-Q	2024-05-07
Q4 2022	-$148M	-$43.7M	-$18.1M	-70.6%	Oct 1, 2022	Dec 31, 2022	10-K	2024-02-26
Q3 2022	-$130M	-$36.8M	-$17M	-85.8%	Jul 1, 2022	Sep 30, 2022	10-Q	2023-11-07
Q2 2022	-$113M	-$35.9M	-$18.6M	-107%	Apr 1, 2022	Jun 30, 2022	10-Q	2023-08-08
Q1 2022	-$94.2M	-$31.4M	-$18.6M	-145%	Jan 1, 2022	Mar 31, 2022	10-Q	2023-05-09
Q4 2021	-$75.6M	-$25.6M	-$14.2M	-124%	Oct 1, 2021	Dec 31, 2021	10-K	2024-02-26
Q3 2021	-$61.4M	-$19.8M	+$37.4M	+65.4%	Jul 1, 2021	Sep 30, 2021	10-Q	2022-11-14
Q2 2021	-$98.7M	-$17.3M	-$9.89M	-134%	Apr 1, 2021	Jun 30, 2021	10-Q	2022-08-09
Q1 2021	-$88.9M	-$12.8M	-$6.66M	-108%	Jan 1, 2021	Mar 31, 2021	10-Q	2022-05-10
Q4 2020	-$82.2M	-$11.5M	-$13.7M	-611%	Oct 1, 2020	Dec 31, 2020	10-K	2022-03-15
Q3 2020	-$68.5M	-$57.2M	-$45.2M	-375%	Jul 1, 2020	Sep 30, 2020	10-Q	2021-11-10
Q2 2020	-$23.3M	-$7.4M	+$3.14M	+29.8%	Apr 1, 2020	Jun 30, 2020	10-Q	2021-08-16
Q1 2020	-$26.5M	-$6.14M	+$5.7M	+48.1%	Jan 1, 2020	Mar 31, 2020	10-Q	2021-05-12
Q4 2019	-$32.2M	$2.24M	+$11.2M		Oct 1, 2019	Dec 31, 2019	10-K	2020-03-26
Q3 2019	-$43.4M	-$12M	-$1.46M	-13.8%	Jul 1, 2019	Sep 30, 2019	10-Q	2020-11-09
Q2 2019	-$42M	-$10.5M	-$1.1M	-11.7%	Apr 1, 2019	Jun 30, 2019	10-Q	2020-08-11
Q1 2019	-$40.9M	-$11.8M	-$4.86M	-69.5%	Jan 1, 2019	Mar 31, 2019	10-Q	2020-05-11
Q4 2018	-$36M	-$9M	-$2.12M	-30.9%	Oct 1, 2018	Dec 31, 2018	10-K	2020-03-26
Q3 2018	-$33.9M	-$10.6M	-$3.41M	-47.5%	Jul 1, 2018	Sep 30, 2018	10-K	2020-03-26
Q2 2018	-$30.5M	-$9.44M	-$3.41M	-56.5%	Apr 1, 2018	Jun 30, 2018	10-K	2020-03-26
Q1 2018	-$27.1M	-$6.99M	-$917K	-15.1%	Jan 1, 2018	Mar 31, 2018	10-K	2020-03-26
Q4 2017	-$26.2M	-$6.88M			Oct 1, 2017	Dec 31, 2017	10-K	2019-03-28
Q3 2017		-$7.17M			Jul 1, 2017	Sep 30, 2017	10-K	2019-03-28
Q2 2017		-$6.03M			Apr 1, 2017	Jun 30, 2017	10-K	2019-03-28
Q1 2017		-$6.07M			Jan 1, 2017	Mar 31, 2017	10-K	2019-03-28

* An asterisk sign (*) next to the value indicates that the value is likely invalid.